Volume 106, Issue 1 pp. 511-520
ORIGINAL ARTICLE - BASIC SCIENCE

Immediate and Early Outcomes Following Myval Octacor Transcatheter Heart Valve Implantation for the Treatment of Patients With Severe Aortic Valve Stenosis: The OCTACOR-EU Study

Alfonso Ielasi

Corresponding Author

Alfonso Ielasi

IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy

Correspondence: Alfonso Ielasi ([email protected])

Search for more papers by this author
Rodolfo Caminiti

Rodolfo Caminiti

IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy

Search for more papers by this author
Arturo Giordano

Arturo Giordano

Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Italy

Search for more papers by this author
Andreas Holzamer

Andreas Holzamer

UniKlinik, Regensburg, Germany

Search for more papers by this author
Giampaolo Vetta

Giampaolo Vetta

Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium

Search for more papers by this author
Luca Testa

Luca Testa

Policlinico San Donato, San Donato Milanese, Italy

Search for more papers by this author
Mihajlo Farkic

Mihajlo Farkic

IKVB Dedinje, Belgrade, Serbia

Search for more papers by this author
Nikolay Stoyanov

Nikolay Stoyanov

University Hospital Saint Anna, Sofia, Bulgaria

Search for more papers by this author
Francesco Gallo

Francesco Gallo

Ospedale dell'Angelo, Mestre, Italy

Search for more papers by this author
Alessia Azzano

Alessia Azzano

Cliniche Gavazzeni, Bergamo, Italy

Search for more papers by this author
Juergen Leick

Juergen Leick

Krankenhaus der Barmherziger Bruder, Trier, Germany

Search for more papers by this author
Federico De Marco

Federico De Marco

Centro Cardiologico Monzino, Milan, Italy

Search for more papers by this author
Mila Kovacevic

Mila Kovacevic

Institute of Cardiovascular Diseases Vojvodina, Sremska Kamenica, Serbia

Search for more papers by this author
Eike Tigges

Eike Tigges

Asklepios Klinik St. Georg, Hamburg, Germany

Search for more papers by this author
Marcin Protasiewicz

Marcin Protasiewicz

Department of Cardiology, Institute of Heart Diseases, Wrocław Medical University, Wroclaw, Poland

Search for more papers by this author
Sebastiano Immè

Sebastiano Immè

Centro Cuore Morgagni Pedara (CT), Pedara, Italy

Search for more papers by this author
Antonio Mangieri

Antonio Mangieri

Istituto Clinico Humanitas, Rozzano (MI), Italy

Search for more papers by this author
Maurizio Tespili

Maurizio Tespili

IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy

Search for more papers by this author
First published: 05 May 2025

ABSTRACT

Background

THV is a standard treatment for elderly patients with severe AS, using either BE or self-expanding (SE) THVs. While the Myval BE THV has demonstrated safety and efficacy, data on its latest iteration, the Octacor, are limited.

Aims

To evaluate the clinical performance of the next-generation Myval Octacor balloon-expandable (BE) transcatheter heart valve (THV) in patients with severe, symptomatic native aortic valve stenosis (AS).

Methods

This observational, real-world, multicenter study involved patients deemed suitable for TAVR and treated with Octacor BE THV at 15 European centers. The primary endpoint was the rate of technical success (exit from procedure room) per VARC-3 criteria. Secondary endpoints included overall mortality, stroke, moderate-to-severe paravalvular leak (PVL), and need for permanent pacemaker (pPM) at 30-day and the longest available follow-up. An analysis by THV sizes (standard −20 to 29 mm vs. XL sizes –30.5 and 32 mm) was performed.

Results

From January to December 2023, 252 patients with severe AS underwent TAVR with the Octacor THV. The average age was 80.6 ± 6.7 years, and the mean STS score was 3.45%. Bicuspid anatomy was reported in 7.1% of cases (standard group 5.4% vs. XL group 20%, p = 0.004). Technical success was achieved in 98.8% of procedures (standard group 99.1% vs. XL group 96.7%, p = 0.2). At 30 days, overall mortality was 1.2%, stroke 3.2%, moderate-to-severe PVL 0.8%, and pPM 16.3%.

Conclusions

The novel BE Myval Octacor THV showed high technical success and favorable early clinical outcomes. Longer follow-up and a head-to-head comparison versus other commercially available THVs are awaited.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.